The influence of sorafenib on hepatic encephalopathy and the mechanistic survey in cirrhotic rats

European Journal of Clinical Investigation

Volumn 42, Issue 12, 2012, Pages 1309-1316

  Hsu, Shao Jung ^a   Hsin, I Fang ^a,b   Lin, Yi Ling ^c   Chen, Yi Chen ^d   Huang, Hui Chun ^a,b   Lee, Fa Yauh ^a,b   Lin, Han Chieh ^a,b   Chang, Ching Chih ^a,b   Lee, Shou Dong ^b,e  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e CHENG HSIN GENERAL HOSPITAL   (Taiwan)

Author keywords

Hepatic encephalopathy; Liver cirrhosis; Oxidative stress; Portal hypertension; Sorafenib

Indexed keywords

ALANINE AMINOTRANSFERASE; AMMONIA; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GLUTATHIONE; MALONALDEHYDE; SORAFENIB; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BILE DUCT LIGATION; BODY WEIGHT; BRAIN CORTEX; BRAIN TISSUE; CEREBELLUM; CONTROLLED STUDY; HEART RATE; HEMODYNAMICS; HEPATIC ENCEPHALOPATHY; HISTOPATHOLOGY; LIVER CIRRHOSIS; MALE; MEAN ARTERIAL PRESSURE; MOTOR ACTIVITY; NONHUMAN; OXIDATIVE STRESS; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; RAT; RISK FACTOR;

ANIMALS; DISEASE MODELS, ANIMAL; HEPATIC ENCEPHALOPATHY; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; NIACINAMIDE; OXIDATIVE STRESS; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84869869780     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12006     Document Type: Article

References (40)

1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
2. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
3. Lipworth AD, Robert C, Zhu AX. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology 2009;77:257-71.
4. Worns MA, Weinmann A, Pfingst K, Schulte-Sasse C, Messow CM, Schulze-Bergkamen H et al. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol 2009;43:489-95.
5. Abdulrahman RM, Verloop H, Hoftijzer H, Verburg E, Hovens GC, Corssmit EP et al. Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. J Clin Endocrinol Metab 2010;95:3758-62.
6. Govindarajan R, Adusumilli J, Baxter DL, El-Khoueiry A, Harik SI. Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006. J Clin Oncol 2006;24:e48.
7. Herden U, Fischer L, Schafer H, Nashan B, von Baehr V, Sterneck M. Sorafenib-induced severe acute hepatitis in a stable liver transplant recipient. Transplantation 2010;90:98-9.
8. Minor DR. Risk of arterial thrombosis not increased by sorafenib or sunitinib. J Clin Oncol 2010;28:e619; author reply e620.
9. Jain L, Sissung TM, Danesi R, Kohn EC, Dahut WL, Kummar S et al. Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res 2010;29:95.
10. Abou-Alfa GK, Amadori D, Santoro A, Figer A, De Greve J, Lathia C et al. Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis. Gastrointest Cancer Res 2011;4:40-4.
11. Ljubuncic P, Tanne Z, Bomzon A. Evidence of a systemic phenomenon for oxidative stress in cholestatic liver disease. Gut 2000;47:710-6.
12. Haussinger D, Gorg B. Interaction of oxidative stress, astrocyte swelling and cerebral ammonia toxicity. Curr Opin Clin Nutr Metab Care 2010;13:87-92.
13. Chiou JF, Tai CJ, Wang YH, Liu TZ, Jen YM, Shiau CY. Sorafenib induces preferential apoptotic killing of a drug- and radio-resistant Hep G2 cells through a mitochondria-dependent oxidative stress mechanism. Cancer Biol Ther 2009;8:1904-13.
14. Kountouras J, Billing BH, Scheuer PJ. Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat. Br J Exp Pathol 1984;65:305-11.
15. Lebrec D, Blanchet L. Effect of two models of portal hypertension on splanchnic organ blood flow in the rat. Clin Sci (Lond) 1985;68:23-8.
16. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109.
17. Chan CY, Lee FY, Wang TF, Huang SW, Chang FY, Lu RH et al. Lack of detrimental or therapeutic effects of cyclooxygenase inhibition in bile duct-ligated rats with hepatic encephalopathy. J Gastroenterol Hepatol 2006;21:1483-7.
18. Bengtsson F, Gage FH, Jeppsson B, Nobin A, Rosengren E. Brain monoamine metabolism and behavior in portacaval-shunted rats. Exp Neurol 1985;90:21-35.
19. Lee FY, Colombato LA, Albillos A, Groszmann RJ. Administration of Nω-nitro-L- arginine ameliorates portal-systemic shunting in portal-hypertensive rats. Gastroenterology 1993;105:1464-70.
20. Chojkier M, Groszmann RJ. Measurement of portal-systemic shunting in the rat by using γ-labeled microspheres. Am J Physiol 1981;240:G371-5.
21. Hodeige D, de Pauw M, Eechaute W, Weyne J, Heyndrickx GR. On the validity of blood flow measurement using colored microspheres. Am J Physiol 1999;276:H1150-8.
22. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351-8.
23. Kakkar P, Das B, Viswanathan PN. A modified spectrophotometric assay of superoxide dismutase. Indian J Biochem Biophys 1984;21:130-2.
24. Arnao MB, Cano A, Hernandez-Ruiz J, Garcia-Canovas F, Acosta M. Inhibition by L-ascorbic acid and other antioxidants of the 2, 20-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) oxidation catalyzed by peroxidase: a new approach for determining total antioxidant status of foods. Anal Biochem 1996;236:255-61.
25. Mejias M, Garcia-Pras E, Tiani C, Miquel R, Bosch J, Fernandez M. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 2009;49:1245-56.
26. Pinter M, Sieghart W, Reiberger T, Rohr-Udilova N, Ferlitsch A, Peck-Radosavljevic M. The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma--a pilot study. Aliment Pharmacol Ther 2012;35:83-91.
27. Coriat R, Gouya H, Mir O, Ropert S, Vignaux O, Chaussade S et al. Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib. PLoS ONE 2011;6:e16978.
28. Bosch J, Pizcueta P, Feu F, Fernández M, Garciá-Pagán JC. Pathophysiology of portal hypertension. Gastroenterol Clin North Am 1992;21:1-14.
29. Fernandez M, Vizzutti F, Garcia-Pagan JC, Rodes J, Bosch J. Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. Gastroenterology 2004;126:886-94.
30. Newman PJ, Berndt MC, Gorski J, White GC, Lyman S, Paddock C et al. PECAM-1 (CD31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamily. Science 1990;247:1219-22.
31. Clemmesen JO, Larsen FS, Kondrup J, Hansen BA, Ott P. Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration. Hepatology 1999;29:648-53.
32. Bernal W, Hall C, Karvellas CJ, Auzinger G, Sizer E, Wendon J. Arterial ammonia and clinical risk factors for encephalopathy and intracranial hypertension in acute liver failure. Hepatology 2007;46:1844-52.
33. Hsin IF, Wang SS, Huang HC, Lee FY, Chan CY, Chang CC et al. Portosystemic collaterals are not prerequisites for the development of hepatic encephalopathy in cirrhotic rats. J Chin Med Assoc 2012;75:3-9.
34. Riggio O, Nardelli S, Moscucci F, Pasquale C, Ridola L, Merli M. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Clin Liver Dis 2012;16:133-46.
35. Vogels BA, van Steynen B, Maas MA, Jorning GG, Chamuleau RA. The effect of ammonia and portal-systemic shunting on brain metabolism, neurotransmission and intracranial hypertension in hyperammonaemia-induced encephalopathy. J Hepatol 1997;26:387 e 95.
36. Kosenko E, Kaminsky Y, Kaminsky A, Valencia M, Lee L, Hermenegildo C et al. Superoxide production and antioxidant enzymes in ammonia intoxication in rats. Free Radic Res 1997;27:637-44.
37. Kosenko E, Kaminski Y, Lopata O, Muravyov N, Felipo V. Blocking NMDA receptors prevents the oxidative stress induced by acute ammonia intoxication. Free Radic Biol Med 1999;26:1369-74.
38. Häussinger D, Schliess F. Pathogenetic mechanisms of hepatic encephalopathy. Gut 2008;57:1156-65.
39. Echeverria V, Burgess S, Gamble-George J, Zeitlin R, Lin X, Cao C et al. Sorafenib inhibits nuclear factor kappa B, decreases inducible nitric oxide synthase and cyclooxygenase-2 expression, and restores working memory in APPswe mice. Neuroscience 2009;162:1220-31.
40. Caraglia M, Giuberti G, Marra M, Addeo R, Montella L, Murolo M et al. Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR. Cell Death Dis 2011;2:e150.